When analyzing the trios, as expected we observed a significant higher expression of FMR1 mRNA in the premutation carriers with FXTAS and without FXTAS compared to control subjects (Figure 3A; p < 0.001 and p < 0.001, respectively, Sellier et al., 2014). This evidence concerns the gene FMR1 and fragile X-associated tremor/ataxia syndrome.